2024-12-23 00:52:45
Author: TopAlliance Biosciences Inc. and The University of Texas Health Science Center at Houston / 2023-07-22 18:32 / Source: TopAlliance Biosciences Inc. and The University of Texas Health Science Center at Houston

TopAlliance and UTHealth Sign a Patent and Technology License Agreement

Access Novel Antibody Technology

Enhance Drug Research and Development

SHANGHAI and HOUSTON,Oct. 10,2018 -- TopAlliance Biosciences Inc. (TopAlliance),a wholly-owned subsidiary of Shanghai Junshi Biosciences Co.,LTD. (Junshi),signed a patent and technology license agreement with The Board of Regents of the University of Texas System on behalf of The University of Texas Health Science Center at Houston (UTHealth). The agreement provides for TopAlliance to use,develop,produce,sell and commercialize product and services based on the patent and technology rights developed in a collaboration between UTHealth and The University of Texas M.D. Anderson Cancer Center (MD Anderson).

The technology covered by the agreement relates to antibodies as therapeutics,which further enhances TopAlliance's technical advantages and core competitiveness in the development of a pipeline of antibody drugs.

"We are very pleased to have signed this license agreement with UTHealth," Dr. Ning Li,Chief Executive Officer of Junshi,commented. "We look forward to building a long-term collaboration with them in the advancement of monoclonal antibody therapeutics."

About Junshi

Founded in 2012,Junshi is an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovative drugs and their clinical research and commercialization on a global scale. The company is the first PRC company to file IND application and NDA with the NMPA for anti-PD-1 monoclonal antibody and the first PRC company to receive IND approvals from the NMPA for anti-PCSK9 monoclonal antibody and anti-BLyS monoclonal antibody. It is one of the first Chinese companies to obtain the IND approval from NMPA for TNF-alpha monoclonal antibody. Its PD-L1 monoclonal antibody also obtained IND approval from NMPA recently.

About UTHealth

Established in 1972 by The University of Texas System Board of Regents,The University of Texas Health Science Center at Houston (UTHealth) is Houston's Health University and Texas' resource for health care education,innovation,scientific discovery and excellence in patient care. The most comprehensive academic health center in the UT Systemand the U.S. Gulf Coast region,UTHealth is home to Jane and Robert Cizik School of Nursing,John P. and Kathrine G. McGovern Medical School,and schools ofbiomedical informatics,biomedical sciences,dentistry and public health. UTHealth includes The University of Texas Harris County Psychiatric Center,as well as the growing clinical practices UT Physicians,UT Dentists and UT Health Services. The university's primary teaching hospitals areMemorial Hermann-Texas Medical Center,Children's Memorial Hermann Hospitaland Harris Health Lyndon B. Johnson Hospital. For more information,visitwww.uth.edu.

Tags: Biotechnology Computer/Electronics Health Care/Hospital Medical/Pharmaceuticals Pharmaceuticals

Previous:

Next:

Leave a comment

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release